Replimune Group Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Priyanka Grover, [Malcolm Kuno and Kalam Smith] from the team. Our first presenting company kicking off the conference is Replimune. And presenting on behalf of the company, we have CEO, Philip Astley-Sparke.
As a reminder, I want to remind all the attendees about the Ask A Question feature in the portal. Please feel free to put all your questions in the portal, and I'm happy to ask on your behalf. With that, Philip, take it away.
Thanks, Anupam. It's a pleasure to be first up at the '22 Life Science JPMorgan Conference. I only wish it could be in person at the St. Francis.
Safe harbor. Replimune. So Replimune is developing an oncolytic immunotherapy platform to maximally activate a systemic immune response against a patient's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |